As reported by The Pennsylvania Record :


More than 75 cases alleging the blood thinner Xarelto caused uncontrollable and sometimes fatal bleeding led Philadelphia Court of Common Pleas Administrative Judge Kevin Dougherty to transfer them to the court’s Complex Litigation Center, The Pennsylvania Record reported.

The plaintiffs petition for transfer claims that the drug’s success was made possible by concealing Xarelto’s deadly effects from prescribing doctors. Defendants Janssen Pharmaceuticals and Bayer Healthcare Pharmaceuticals manufacture the oral anticoagulant. As reported in the Record, Janssen responded to the decision with a press statement that the medication’s risks have been openly provided to prescribing doctors and their patients.


HB Litigation Conferences Presents

Mass Tort Med School:
A Bootcamp for Plaintiff Attorneys

Boca Raton

May 6-8, 2015